BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Klug LR, Khosroyani HM, Kent JD, Heinrich MC. New treatment strategies for advanced-stage gastrointestinal stromal tumours. Nat Rev Clin Oncol 2022;19:328-41. [PMID: 35217782 DOI: 10.1038/s41571-022-00606-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Naito Y, Nishida T, Doi T. Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours. Gastric Cancer 2023. [PMID: 36913072 DOI: 10.1007/s10120-023-01381-6] [Reference Citation Analysis]
2 Xu W, Yang M, Du X, Peng H, Yang Y, Wang J, Zhang Y. Multifunctional Nanoplatform Based on Sunitinib for Synergistic Phototherapy and Molecular Targeted Therapy of Hepatocellular Carcinoma. Micromachines 2023;14:613. [DOI: 10.3390/mi14030613] [Reference Citation Analysis]
3 Li C, Gao Z, Cui Z, Liu Z, Bian Y, Sun H, Wang N, He Z, Li B, Li F, Li Z, Wang L, Zhang D, Yang L, Xu Z, Xu H. Deubiquitylation of Rab35 by USP32 promotes the transmission of imatinib resistance by enhancing exosome secretion in gastrointestinal stromal tumours. Oncogene 2023;42:894-910. [PMID: 36725886 DOI: 10.1038/s41388-023-02600-1] [Reference Citation Analysis]
4 Unk M, Jezeršek Novaković B, Novaković S. Molecular Mechanisms of Gastrointestinal Stromal Tumors and Their Impact on Systemic Therapy Decision. Cancers (Basel) 2023;15. [PMID: 36900287 DOI: 10.3390/cancers15051498] [Reference Citation Analysis]
5 Huang S, Liu X, Guo X, Wu H, Lu H, Pan Z, Cai S, Wu X, Zhang X. Sunitinib versus imatinib dose escalation after failure of imatinib standard dose in patients with advanced Gastrointestinal stromal tumors - a real-world multi-center study. Transl Oncol 2023;30:101641. [PMID: 36791510 DOI: 10.1016/j.tranon.2023.101641] [Reference Citation Analysis]
6 Zhang H, Mu M, He X, Yin Y. Surgical treatment of the metastatic gastrointestinal stromal tumor after resistance to available tyrosine kinase inhibitors: A case report. Asian J Surg 2023;46:937-8. [PMID: 35963693 DOI: 10.1016/j.asjsur.2022.07.066] [Reference Citation Analysis]
7 zhang X, Zhang A, Zhang J, Xia H, Gu X, Ding L, Zhang X, Yin W. The efficacy and adverse events of regorafenib in advanced gastrointestinal stromal tumors after imatinib and sunitinib failure: a systemic review and meta-analysis.. [DOI: 10.21203/rs.3.rs-2391619/v1] [Reference Citation Analysis]
8 Khosroyani HM, Klug LR, Heinrich MC. TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors. Drugs 2023;83:55-73. [PMID: 36607590 DOI: 10.1007/s40265-022-01820-1] [Reference Citation Analysis]
9 Cao Z, Li J, Sun L, Xu Z, Ke Y, Shao B, Guo Y, Sun Y. GISTs with NTRK Gene Fusions: A Clinicopathological, Immunophenotypic, and Molecular Study. Cancers (Basel) 2022;15. [PMID: 36612101 DOI: 10.3390/cancers15010105] [Reference Citation Analysis]
10 Mathias-machado MC, de Jesus VHF, de Carvalho Oliveira LJ, Neumann M, Peixoto RD. Current Molecular Profile of Gastrointestinal Stromal Tumors and Systemic Therapeutic Implications. Cancers 2022;14:5330. [DOI: 10.3390/cancers14215330] [Reference Citation Analysis]
11 Fung S, Shirley M. Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy. Drugs 2022. [DOI: 10.1007/s40265-022-01794-0] [Reference Citation Analysis]
12 Liu GH, Chen T, Zhang X, Ma XL, Shi HS. Small molecule inhibitors targeting the cancers. MedComm (2020) 2022;3:e181. [PMID: 36254250 DOI: 10.1002/mco2.181] [Reference Citation Analysis]
13 Khachatryan V, Muazzam A, Hamal C, Velugoti LSDR, Tabowei G, Gaddipati GN, Mukhtar M, Alzubaidee MJ, Dwarampudi RS, Mathew S, Bichenapally S, Mohammed L. The Role of Regorafenib in the Management of Advanced Gastrointestinal Stromal Tumors: A Systematic Review. Cureus 2022. [DOI: 10.7759/cureus.28665] [Reference Citation Analysis]
14 Papadakos SP, Tsagkaris C, Papadakis M, Papazoglou AS, Moysidis DV, Zografos CG, Theocharis S. Angiogenesis in gastrointestinal stromal tumors: From bench to bedside. World J Gastrointest Oncol 2022; 14(8): 1469-1477 [DOI: 10.4251/wjgo.v14.i8.1469] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Guo Q, Liu L, Chen Z, Fan Y, Zhou Y, Yuan Z, Zhang W. Current treatments for non-small cell lung cancer. Front Oncol 2022;12:945102. [DOI: 10.3389/fonc.2022.945102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Jiang W, Zhao T, Zhen X, Jin C, Li H, Ha J. Rapid Determination of 9 Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma in Human Plasma by QuEChERS-UPLC-MS/MS. Front Pharmacol 2022;13:920436. [DOI: 10.3389/fphar.2022.920436] [Reference Citation Analysis]